▎ 摘　　要

NOVELTY - Immune cell therapy agent for atherosclerotic plaque, is based on mononuclear macrophages (M), membrane modification material, preferably cluster of differentiation (CD)47p, a nano-assisted intermediate carrier, preferably graphene quantum dots (GQDs) and a gene drug of miRNA223, where a cross-linked system of M-CD47p-GQDs-miRNA223 is constructed by cell surface nano-engineering technology. USE - Immune cell therapeutic agent for atherosclerotic plaques. ADVANTAGE - The immune cell therapeutic agent delivers a medicine to the atherosclerotic lesions accurately and targetedly, thus solving a problem that the treatment effect obtained by the systemic nonspecific distribution of the medicine in the AS non-invasive treatment is not obvious. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for preparing the immune cell therapeutic agent, which involves: a. adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide to a dissolved CD47p solution, adjusting the pH to 6, and stirring at room temperature for 30 minutes to obtain a carboxyl group activated CD47p solution A; b. adding an aminated GQDs solution to the solution A, adjusting the pH to 7.44, stirring at room temperature for 24 hours, dialyzing to obtain CD47p-GQDs cross-linking solution, adding 6-(3'-(2-pyridyldithio)propionylamino)hexanoate to the cross-linking solution, stirring at room temperature for 1 hour, performing ultrafiltration and centrifugation to obtain the CD47p-GQDs-S-S-solution, as solution C; c. adding a thiolated miRNA223 solution to the solution C, placing it in a refrigerator at 4°C and keeping it away from light for overnight reaction to obtain a CD47p-GQDs-miRNA223 solution, which is denoted as solution D; and d. co-incubating the solution D with RAW264.7 monocyte-macrophages to obtain the immune cell therapeutic agent (M-CD47p-GQDs-miRNA223), where the room temperature is 20-25°C.